Abstract
A large variety of drugs have been reported to cause peripheral neuropathies as dose-limiting adverse effects; however, most of them primarily affect axons and/or neuronal cell bodies rather than Schwann cells and/or myelin sheaths. In this chapter, we focus on the drugs that seem to elicit the neuropathies with schwannopathy and/or myelinopathy-predominant phenotypes, such as amiodarone, dichloroacetate, and tumor necrosis factor-α antagonists. Although the pathogenesis of demyelination induced by these drugs remain largely obscure, the recent in vivo and in vitro studies have implicated the involvement of metabolic abnormalities and impaired autophagy in Schwann cells and immune system disorders in the disruption of neuron–Schwann cell contact and interactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Argyriou AA (2015) Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics 3(2):187–197. https://doi.org/10.3390/toxics3020187
Bilbao JM, Schmidt RE (2015) Biopsy diagnosis of peripheral neuropathy. Springer, Cham. ISBN:978-3-319-07311-8
Bosch X, Saiz A, Ramos-Casals M (2011) Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 7(3):165–172. https://doi.org/10.1038/nrneurol.2011.1
Brandsma D, Dorlo TP, Haanen JH, Beijnen JH, Boogerd W (2010) Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol 257(12):2099–2100. https://doi.org/10.1007/s00415-010-5654-9
Buyukakilli B, Atici A, Balli E, Ozkan A, Gurgul S, Tasdelen B, Dagtekin O (2014) Effects of a tumor necrosis factor-alpha inhibitor (etanercept) on the sciatic nerve in a hypoxic ischemia-induced neonatal rat model. Adv Clin Exp Med 23(5):705–713
Calcutt NA, Lopez VL, Bautista AD, Mizisin LM, Torres BR, Shroads AL, Mizisin AP, Stacpoole PW (2009) Peripheral neuropathy in rats exposed to dichloroacetate. J Neuropathol Exp Neurol 68(9):985–993. https://doi.org/10.1097/NEN.0b013e3181b40217
Chen X, Oppenheim JJ (2011) Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett 585(23):3611–3618. https://doi.org/10.1016/j.febslet.2011.04.025
Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185(9):1573–1584
Crowell A, Gwathmey KG (2017) Sensory neuronopathies. Curr Neurol Neurosci Rep 17(10):79. https://doi.org/10.1007/s11910-017-0784-4
Fardeau M, Tome FM, Simon P (1979) Muscle and nerve changes induced by perhexiline maleate in man and mice. Muscle Nerve 2(1):24–36. https://doi.org/10.1002/mus.880020105
Felitsyn N, Stacpoole PW, Notterpek L (2007) Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect. J Neurochem 100(2):429–436. https://doi.org/10.1111/j.1471-4159.2006.04248.x
Fernandez-Menendez S, Gonzalez Nafria N, Redondo-Robles L, Sierra-Ausin M, Garcia-Santiago R, Saponaro-Gonzalez A (2015) Multifocal-motor-neuropathy-like disease associated with infliximab treatment in a patient with Crohn’s disease. J Neurol Sci 349(1–2):246–248. https://doi.org/10.1016/j.jns.2015.01.003
Hall SM, Redford EJ, Smith KJ (2000) Tumour necrosis factor-alpha has few morphological effects within the dorsal columns of the spinal cord, in contrast to its effects in the peripheral nervous system. J Neuroimmunol 106(1–2):130–136
Han Y, Smith MT (2013) Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol 4:156. https://doi.org/10.3389/fphar.2013.00156
Han Y, Miller A, Mangada J, Liu Y, Swistowski A, Zhan M, Rao MS, Zeng X (2009) Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One 4(9):e7155. https://doi.org/10.1371/journal.pone.0007155
Hoke A (2012) Animal models of peripheral neuropathies. Neurotherapeutics 9(2):262–269. https://doi.org/10.1007/s13311-012-0116-y
Hung YH, Chen LM, Yang JY, Yang WY (2013) Spatiotemporally controlled induction of autophagy-mediated lysosome turnover. Nat Commun 4:2111. https://doi.org/10.1038/ncomms3111
Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M (2013) Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51(5):618–631. https://doi.org/10.1016/j.molcel.2013.08.003
James MO, Stacpoole PW (2016) Pharmacogenetic considerations with dichloroacetate dosing. Pharmacogenomics 17(7):743–753. https://doi.org/10.2217/pgs-2015-0012
James MO, Jahn SC, Zhong G, Smeltz MG, Hu Z, Stacpoole PW (2017) Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacol Ther 170:166–180. https://doi.org/10.1016/j.pharmthera.2016.10.018
Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30(10):2287–2291
Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9(5):463–472. https://doi.org/10.1016/j.jpain.2008.01.335
Kalliolias GD, Ivashkiv LB (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 12(1):49–62. https://doi.org/10.1038/nrrheum.2015.169
Katz R, Tai CN, Diener RM, McConnell RF, Semonick DE (1981) Dichloroacetate, sodium: 3-month oral toxicity studies in rats and dogs. Toxicol Appl Pharmacol 57(2):273–287
Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, Millar WS, Hong X, Gooch CL, Mao X, Pascual JM, Hirano M, Stacpoole PW, DiMauro S, De Vivo DC (2006) Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66(3):324–330. https://doi.org/10.1212/01.wnl.0000196641.05913.27
Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 8:86. https://doi.org/10.3389/fphar.2017.00086
Little AA, Albers JW (2015) Clinical description of toxic neuropathies. Handb Clin Neurol 131:253–296. https://doi.org/10.1016/b978-0-444-62627-1.00015-9
London Z, Albers JW (2007) Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin 25(1):257–276. https://doi.org/10.1016/j.ncl.2006.10.001
Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401–426. https://doi.org/10.1146/annurev-pharmtox-011112-140320
Manji H (2013) Drug-induced neuropathies. Handb Clin Neurol 115:729–742. https://doi.org/10.1016/b978-0-444-52902-2.00042-4
Marmiroli P, Nicolini G, Miloso M, Scuteri A, Cavaletti G (2012) The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity. Ital J Anat Embryol 117(2):75–97
Misawa S, Kuwabara S, Mori M, Kawaguchi N, Yoshiyama Y, Hattori T (2001) Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 56(5):666–669
Niimi N, Yako H, Tsukamoto M, Takaku S, Yamauchi J, Kawakami E, Yanagisawa H, Watabe K, Utsunomiya K, Sango K (2016) Involvement of oxidative stress and impaired lysosomal degradation in amiodarone-induced schwannopathy. Eur J Neurosci 44(1):1723–1733. https://doi.org/10.1111/ejn.13268
Niimi N, Takaku S, Yako H, Sango K (2017) Immortalized Schwann cells IFRS1 as a new strategic tool for the study of myelination and demyelination. Med Res Arch 5(2). https://journals.kei.org/index.php/mra/article/view/1028
Orr CF, Ahlskog JE (2009) Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 66(7):865–869. https://doi.org/10.1001/archneurol.2009.96
Pomponio G, Zurich MG, Schultz L, Weiss DG, Romanelli L, Gramowski-Voss A, Di Consiglio E, Testai E (2015) Amiodarone biokinetics, the formation of its major oxidative metabolite and neurotoxicity after acute and repeated exposure of brain cell cultures. Toxicol In Vitro 30(1 Pt A):192–202. https://doi.org/10.1016/j.tiv.2015.01.012
Pulipaka U, Lacomis D, Omalu B (2002) Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis 3(3):97–105
Punnam SR, Goyal SK, Kotaru VP, Pachika AR, Abela GS, Thakur RK (2010) Amiodarone - a ‘broad spectrum’ antiarrhythmic drug. Cardiovasc Hematol Disord Drug Targets 10(1):73–81
Rao DB, Jortner BS, Sills RC (2014) Animal models of peripheral neuropathy due to environmental toxicants. ILAR J 54(3):315–323. https://doi.org/10.1093/ilar/ilt058
Ratnarajan G, Thompson A, Dodridge C, Parry A, Elston J (2015) Novel variant of Miller Fisher syndrome occurring with tumor necrosis factor alpha antagonist therapy. JAMA Neurol 72(11):1377–1378. https://doi.org/10.1001/jamaneurol.2015.2251
Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J (2005) Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 64(8):1468–1470. https://doi.org/10.1212/01.wnl.0000158681.29117.8b
Rusinova R, Koeppe RE 2nd, Andersen OS (2015) A general mechanism for drug promiscuity: studies with amiodarone and other antiarrhythmics. J Gen Physiol 146(6):463–475. https://doi.org/10.1085/jgp.201511470
Sango K, Saito H, Takano M, Tokashiki A, Inoue S, Horie H (2006) Cultured adult animal neurons and Schwann cells give us new insights into diabetic neuropathy. Curr Diabetes Rev 2(2):169–183
Sango K, Yanagisawa H, Kawakami E, Takaku S, Ajiki K, Watabe K (2011) Spontaneously immortalized Schwann cells from adult Fischer rat as a valuable tool for exploring neuron-Schwann cell interactions. J Neurosci Res 89(6):898–908. https://doi.org/10.1002/jnr.22605
Sango K, Kawakami E, Yanagisawa H, Takaku S, Tsukamoto M, Utsunomiya K, Watabe K (2012) Myelination in coculture of established neuronal and Schwann cell lines. Histochem Cell Biol 137(6):829–839. https://doi.org/10.1007/s00418-012-0934-3
Schmitt LI, Leo M, Kleinschnitz C, Hagenacker T (2018) Oxaliplatin modulates the characteristics of voltage-gated calcium channels and action potentials in small dorsal root ganglion neurons of rats. Mol Neurobiol 55(12):8842–8855. https://doi.org/10.1007/s12035-018-1029-5. [Epub ahead of print]
Silburn S, McIvor E, McEntegart A, Wilson H (2008) Guillain-Barre syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis 67(4):575–576. https://doi.org/10.1136/ard.2005.043208
Silva A, Wang Q, Wang M, Ravula SK, Glass JD (2006) Evidence for direct axonal toxicity in vincristine neuropathy. J Peripher Nerv Syst 11(3):211–216. https://doi.org/10.1111/j.1529-8027.2006.0090.x
Spruijt L, Naviaux RK, McGowan KA, Nyhan WL, Sheean G, Haas RH, Barshop BA (2001) Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve 24(7):916–924
Stubgen JP (2008) Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37(3):281–292. https://doi.org/10.1002/mus.20924
Stubgen JP (2011) Drug-induced dysimmune demyelinating neuropathies. J Neurol Sci 307(1–2):1–8. https://doi.org/10.1016/j.jns.2011.05.010
Ta LE, Espeset L, Podratz J, Windebank AJ (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27(6):992–1002. https://doi.org/10.1016/j.neuro.2006.04.010
Takaku S, Yako H, Niimi N, Akamine T, Kawanami D, Utsunomiya K, Sango K (2018) Establishment of a myelinating co-culture system with a motor neuron-like cell line NSC-34 and an adult rat Schwann cell line IFRS1. Histochem Cell Biol 149(5):537–543. https://doi.org/10.1007/s00418-018-1649-x
Tegner R, Tome FM, Godeau P, Lhermitte F, Fardeau M (1988) Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol 75(3):253–260
Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257(9):1421–1431. https://doi.org/10.1007/s00415-010-5591-7
Van Helleputte L, Kater M, Cook DP, Eykens C, Rossaert E, Haeck W, Jaspers T, Geens N, Vanden Berghe P, Gysemans C, Mathieu C, Robberecht W, Van Damme P, Cavaletti G, Jarpe M, Van Den Bosch L (2018) Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiol Dis 111:59–69. https://doi.org/10.1016/j.nbd.2017.11.011
Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298(11):1312–1322. https://doi.org/10.1001/jama.298.11.1312
Acknowledgments
We thank Drs. Tsuneo Iiai, Junji Yamauchi, Kazuhiko Watabe, Mari Suzuki, and Tomoyo Akamine for helpful suggestions, Emiko Kawakami, Kentaro Endo, and late Kyoko Ajiki for technical assistance with our studies.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Niimi, N., Takaku, S., Yako, H., Sango, K. (2019). Drug-Induced Demyelinating Neuropathies. In: Sango, K., Yamauchi, J., Ogata, T., Susuki, K. (eds) Myelin. Advances in Experimental Medicine and Biology, vol 1190. Springer, Singapore. https://doi.org/10.1007/978-981-32-9636-7_23
Download citation
DOI: https://doi.org/10.1007/978-981-32-9636-7_23
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9635-0
Online ISBN: 978-981-32-9636-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)